A Randomized Phase IV Study Comparing Enzalutamide Versus Flutamide in Castration-resistant Prostate Cancer (CRPC) Patients Who Have Failed Combined Androgen Blockade Therapy With Bicalutamide Plus Androgen Deprivation Therapy (ADT)
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Enzalutamide (Primary) ; Flutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms AFTERCAB
- Sponsors Astellas Pharma
- 13 Feb 2021 Primary endpoint has been met. (Time to prostate specific antigen (PSA) progression with 1st line AAT)
- 13 Feb 2021 Results presented at the 2021 Genitourinary Cancers Symposium
- 14 Apr 2020 Status changed from active, no longer recruiting to completed.